Astra vs. Janssen: The blood clot battle

Thrombosis and thrombocytopenia

“Cases presenting as venous thrombosis, including unusual sites such as cerebral venous sinus thrombosis, splanchnic vein thrombosis, as well as arterial thrombosis, concomitant with thrombocytopenia. The majority of the events occurred within the first 21 days following vaccination but have also been reported after this period. Some events had a fatal outcome.” (Astra. Sect. 4.4, pp. 3-4)

“The reporting rate of thrombosis with thrombocytopenia following administration of the Janssen COVID-19 Vaccine has been highest in females ages 18 through 49 years; some cases have been fatal.” (Janssen. Warnings, p. 3)

Verdict: Astra, well done. You admitted the deaths from your product. However, Janssen went one step further and specified the age group.

Janssen wins by TKO.